Undisclosed · Other round · Software · Zurich, Switzerland
Zurich-based DataHow has closed an undisclosed bridge financing round extending its Series A, led by existing investor Momenta, with continued participation from Rockwell Automation, HINA Bioventures and Zürcher Kantonalbank. According to the company announcement, the capital will accelerate real-time connectivity, model-driven process control and expansion into downstream bioprocessing.
DataHow builds software for biopharmaceutical development and manufacturing. Its DataHowLab platform combines coded process knowledge with data-driven AI, an approach designed for processes where experiments are expensive and datasets are smaller than those used by general-purpose machine-learning systems. The company says the platform is deployed with many large biopharmaceutical manufacturers and that its wider partner base includes 12 of the top 20 Big Pharma companies.
From process insight to operational guidance
The bridge round is funding a move from analysing historical experiments toward connecting models directly to laboratory and production systems. DataHow describes the near-term step as human-in-the-loop guidance, with model-driven disturbance rejection, optimisation and control as the longer-term direction. That matters commercially because software embedded in live process decisions can become more valuable than a standalone analysis tool, but it also carries a higher implementation burden.
Real-time recommendations need reliable data connections, clear operating limits and enough trust from process engineers to influence expensive production runs. Existing investor Rockwell Automation is relevant here as both an industrial automation specialist and an OEM collaborator. Lead investor Momenta’s investment rationale frames DataHow’s opportunity as converting process knowledge into decisions closer to the point of execution.
Extending the platform beyond upstream processing
DataHow is also using the financing to extend DataHowLab from its established upstream capabilities into downstream processing, where biologic products are separated, purified and prepared after production. The company’s June 2026 product release already added downstream tools for mRNA workflows alongside process characterisation, specifications and multi-objective optimisation.
A broader platform can let customers reuse models and specifications across more of the development lifecycle, rather than handing data between disconnected tools. The execution test is whether DataHow can preserve the scientific context that makes its hybrid models useful as it adds real-time integrations and more unit operations. Founded from ETH Zurich research in 2017, the company previously raised its Series A in 2024; this undisclosed bridge extends that round rather than presenting a new priced series.
